(Surgery for Obesity and Related Diseases, 2023) reported mean weight loss of approximately 10-12% with semaglutide in post-bariatric patients over 612 months, though results varied considerably between individuals
2 Every FSA/HSA plan is unique, and Noom does not provide medical, healthcare benefit, or tax advice to individuals
Experience the difference with Carniwel Pet Food and Celebrate Pet Parenting - where taste, health, and care come together for your furry family member
GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators
Supplements can come in various forms, such as tablets or powders mixed with water
